ROQ vs. IXI, BVX, FAB, CIZ, HEMO, APTA, GENF, EVG, MTFB, and DEST
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include IXICO (IXI), BiVictriX Therapeutics (BVX), Fusion Antibodies (FAB), Cizzle Biotechnology (CIZ), Hemogenyx Pharmaceuticals (HEMO), Aptamer Group (APTA), Genflow Biosciences (GENF), Evgen Pharma (EVG), Motif Bio (MTFB), and Destiny Pharma (DEST). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs.
IXICO (LON:IXI) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
56.0% of IXICO shares are held by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are held by institutional investors. 30.3% of IXICO shares are held by company insiders. Comparatively, 60.4% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Roquefort Therapeutics has lower revenue, but higher earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
IXICO has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.
In the previous week, IXICO's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.
IXICO has a net margin of -31.10% compared to Roquefort Therapeutics' net margin of -57,057.07%. IXICO's return on equity of -19.14% beat Roquefort Therapeutics' return on equity.
IXICO received 144 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
Summary
IXICO beats Roquefort Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy ROQ Stock Free ROQ Stock Alerts